
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017
- Volume 12
- Issue 10
Ajinomoto Althea Adds High Potency Capabilities
Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.
Ajinomoto Althea, Inc. announced on Sept. 19, 2017 that the company will open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility in San Diego, CA. The facility is designed to develop, manufacture, test, and release HPPs including antibody drug conjugates, highly potent APIs, and other complex formulations of highly potent drugs.
The company currently offers process development and analytical services to clients from the facility and will be open for GMP bioconjugation and complex formulation in November 2017. Full manufacturing services, including high containment fill and finish, will commence in Q4 2018, as reported in a press statement on Sept. 19, 2017.
The company also announced that it secured its first manufacturing contract for the new facility.
Source:
Articles in this issue
about 8 years ago
Finding a New Purpose for an Unproven Drugabout 8 years ago
Demand for Efficiency Spurs Bioprocessing Innovationabout 8 years ago
Fresenius Kabi Breaks Ground on $250-Million Facility Expansionabout 8 years ago
UPS Reveals Supply Chain Security Systemabout 8 years ago
Cambrex Adds Reactors to Facility in Swedenabout 8 years ago
ADC Bio Invests $11 Million on Bioconjugation Facilityabout 8 years ago
Software Adds Data Integrity Functionsabout 8 years ago
Particle Analyzer Images Nanoparticlesabout 8 years ago
Global Effort to Stop Sale of Illegal Drugs Advancesabout 8 years ago
BASF Plans Amine Facility in NanjingNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





